Cerevasc today announced the first-in-human use of its eShunt system to treat medically refractory idiopathic intracranial hypertension (IIH).
CereVasc, Inc., a clinical-stage medical device company developing novel minimally invasive treatments for neurological diseases, today announced the publication of a first-in-human case report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results